Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population with Obesity

Launched by CR-CSSS CHAMPLAIN-CHARLES-LE MOYNE · Nov 13, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how effective a specific antibiotic called piperacillin-tazobactam is for treating infections in patients who are obese. The researchers want to find out if giving the medication in a special way, called prolonged intermittent infusion, can help it work better compared to the standard method of giving it. They will be measuring how well the drug reaches its target in the body after 24 hours of treatment.

To be part of this study, participants need to be adults aged 18 or older who are currently hospitalized at Hôpital Charles-Le Moyne and have a body mass index (BMI) of 30 or higher, which indicates obesity. They also need to have started treatment with piperacillin-tazobactam within the last day and be expected to receive it for at least 24 hours. However, people who are pregnant, have certain medical conditions like severe allergies to penicillin, or are undergoing specific types of dialysis are not eligible. Those who join the study can expect to receive the medication while being closely monitored, helping researchers understand how to improve treatment for infections in obese patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults (18 years and older)
• • Patients hospitalized at Hôpital Charles-Le Moyne
• • Obesity (as defined by a body mass index of ≥ 30 kg/m\^2)
• • Piperacillin-tazobactam prescription initiated within last 24 hours
• • Planned duration of piperacillin-tazobactam of 24 hours or more
• Exclusion Criteria:
• • Documented allergy to beta-lactams of the penicillin class
• • Patients with renal replacement therapy (hemodialysis, peritoneal dialysis, continuous venovenous hemodiafiltration)
• • Pregnancy
• • History of seizures or epilepsy, active seizures or epilepsy treated with antiepileptic drug therapy
• • Patients on prolonged intermittent infusion or continuous infusion of piperacillin-tazobactam before randomization